Scholar Rock (NASDAQ:SRRK) Shares Gap Up – Here’s What Happened

Scholar Rock Holding Corporation (NASDAQ:SRRK) shares gapped up prior to trading on Tuesday . The stock had previously closed at $43.08, but opened at $47.67. Scholar Rock shares last traded at $49.5450, with a volume of 546,840 shares.

Scholar Rock News Summary

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Company resubmitted its FDA filing for apitegromab, prompting a sharp market reaction and setting up a potential regulatory decision around September 2026 — a clear near‑term catalyst if the FDA accepts and completes review. Read More.
• Positive Sentiment: Multiple outlets report the stock surged on the FDA resubmission, reinforcing market optimism that the program’s regulatory pathway is back on track. That reaction increases attention and trading liquidity around SRRK. Read More.
• Positive Sentiment: Analysts are upbeat: Wedbush raised its price target to $58 and kept an “Outperform” rating, implying meaningful upside from current levels — a broker upgrade that can attract more institutional interest. Read More.
• Neutral Sentiment: Company management discussed the BLA resubmission and regulatory progress in a recent transcript; details there may clarify the approval strategy, outstanding FDA questions, and the expected review timeline — useful for assessing probability of approval and timing. Read More.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on SRRK shares. BMO Capital Markets increased their target price on Scholar Rock from $50.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, March 4th. JPMorgan Chase & Co. lifted their price target on Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, March 16th. UBS Group began coverage on Scholar Rock in a research report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective for the company. Barclays increased their price objective on Scholar Rock from $52.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday, March 3rd. Finally, Citigroup raised their target price on shares of Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $54.93.

Scholar Rock Trading Up 0.4%

The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $5.67 billion, a PE ratio of -14.39 and a beta of 0.70. The stock’s fifty day moving average price is $45.17 and its two-hundred day moving average price is $40.68.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same period in the previous year, the company posted ($0.64) EPS. Sell-side analysts anticipate that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Mo Qatanani sold 8,484 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $47.07, for a total value of $399,341.88. Following the completion of the sale, the insider owned 98,445 shares of the company’s stock, valued at $4,633,806.15. This trade represents a 7.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Caryn Parlavecchio sold 9,035 shares of Scholar Rock stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $420,398.55. Following the completion of the sale, the insider owned 169,087 shares in the company, valued at approximately $7,867,618.11. This trade represents a 5.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 207,464 shares of company stock valued at $9,157,423 in the last 90 days. 13.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. IFP Advisors Inc lifted its position in shares of Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after purchasing an additional 450 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Scholar Rock during the fourth quarter valued at about $30,000. Summit Securities Group LLC bought a new position in Scholar Rock in the fourth quarter worth about $31,000. Ramirez Asset Management Inc. bought a new position in Scholar Rock in the third quarter worth about $37,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after buying an additional 525 shares during the period. 91.08% of the stock is currently owned by institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).